CRISPR Therapeutics (CRSP) PT Lowered to $98 at Jefferies

May 5, 2026 7:39 AM

Jefferies analyst Maury Raycroft lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $98.00 (from $100.00) while maintaining a Buy rating.

No results found